Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expressionWenkai Ye(Zhejiang Chinese Medical University), Xia Li(Zhejiang Chinese Medical University)Medical OncologyDecember 30, 202510.1007/s12032-025-03222-1Cited by 0SaveCiteExport RISWatch citationsRelated PapersExosomal miRNA423-5p mediated oncogene activity in papillary thyroid carcinoma: a potential diagnostic and biological target for cancer therapy|Neoplasma|2019|26